In­no­force opens new man­u­fac­tur­ing site in Chi­na

In­no­force is off to the races at its new site in the city of Hangzhou, Chi­na.

The Chi­nese CD­MO an­nounced last week that it has start­ed man­u­fac­tur­ing at the new fa­cil­i­ty, which was built to of­fer process de­vel­op­ment and man­u­fac­tur­ing op­er­a­tions for RNA, plas­mid DNA, vi­ral vec­tors and oth­er cell ther­a­peu­tics. It will al­so serve as In­no­force’s cor­po­rate HQ.

The com­pa­ny said it’s in­vest­ing more than $200 mil­lion in the 550,000-square-foot man­u­fac­tur­ing base for ad­vanced ther­a­pies. The GMP man­u­fac­tur­ing fa­cil­i­ty fea­tures space for pro­duc­ing plas­mids with three 30-liter biore­ac­tors. For vi­ral vec­tor man­u­fac­tur­ing, In­no­force al­so has 200- and 500-liter biore­ac­tors at its dis­pos­al, along with eight suites to make cell ther­a­pies. The site al­so in­cludes sev­er­al labs and ware­house spaces.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER